Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib

Clin Lung Cancer. 2019 Jan;20(1):59-62. doi: 10.1016/j.cllc.2018.09.009. Epub 2018 Sep 21.
No abstract available

Keywords: Concomitant driver mutations; Epithelial growth factor receptor; Next generation sequencing; Non small cell lung cancer; TKI combination.

Publication types

  • Case Reports

MeSH terms

  • Afatinib / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Crizotinib / therapeutic use*
  • ErbB Receptors / genetics
  • Exons / genetics
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Middle Aged
  • Mutation / genetics
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins c-met / genetics*
  • Remission Induction

Substances

  • Protein Kinase Inhibitors
  • Afatinib
  • Crizotinib
  • EGFR protein, human
  • ErbB Receptors
  • MET protein, human
  • Proto-Oncogene Proteins c-met